skip to main content

H.R. 3348 (115th): Adding Middle East Respiratory Syndrome to the FDA Priority Review Voucher Program Act

The text of the bill below is as of Jul 20, 2017 (Introduced).


I

115th CONGRESS

1st Session

H. R. 3348

IN THE HOUSE OF REPRESENTATIVES

July 20, 2017

(for himself, Mr. Brendan F. Boyle of Pennsylvania, Mr. Marshall, and Mr. Rothfus) introduced the following bill; which was referred to the Committee on Energy and Commerce

A BILL

To expand the tropical disease product priority review voucher program to encourage treatments for the Middle East respiratory syndrome.

1.

Short title

This Act may be cited as the Adding Middle East Respiratory Syndrome to the FDA Priority Review Voucher Program Act.

2.

Expanding tropical disease product priority review voucher program to encourage treatments for Middle East respiratory syndrome

Section 524(a)(3) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360n(a)(3)) is amended—

(1)

by redesignating subparagraph (S) as subparagraph (T); and

(2)

by inserting after subparagraph (R) the following:

(S)

Middle East respiratory syndrome.

.

{# }